Chongqing Zhifei Biological Products Co (300122) investor relations material

Executive summary

• 2025 marked the first annual net loss since listing, driven by industry downturn, weak product sales, and significant asset impairment.

• Strategic shift from commercial to innovation-driven model led to short-term operational shocks.

• Liquidity pressures were actively managed through financing, debt restructuring, and working capital optimization.

• R&D investment remained high, with 14.36 billion RMB spent, supporting a robust pipeline.

• Strategic partnerships with GSK and Merck were restructured to reduce inventory and market risk.

Financial highlights

• Revenue for 2025 was RMB 8.96 billion, down 65.61% year-over-year.

• Net loss attributable to shareholders was RMB -14.72 billion, compared to a profit of RMB 1.97 billion in 2024.

• Gross margin for self-developed products was 70.62%, while for agency products it was 1.23%.

• Operating cash flow turned positive at RMB 5.17 billion, up 222% from last year.

• Total assets at year-end were RMB 31.72 billion, down 38.16% from the prior year.

• No cash dividend, bonus shares, or capital reserve transfer was proposed for 2025.

Outlook and guidance

• Focus remains on accelerating the commercialization of self-developed products and optimizing revenue structure.

• Five products are in the registration phase, with several expected to launch in the next 2–3 years.

• Continued high R&D investment and international expansion are planned.

• Enhanced risk management and cash flow discipline will be maintained.